Onconova Implementation Guide
0.2.0 - ci-build

Onconova Implementation Guide - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Artifacts Summary
.... 2.1 Onconova FHIR REST Capability Statement
.... 2.2 Adverse Event Profile
.... 2.3 Aneuploid Score Profile
.... 2.4 Cancer Family Member History
.... 2.5 Cancer Patient Profile
.... 2.6 Cancer Risk Assessment Profile
.... 2.7 Cancer Stage
.... 2.8 Comorbidities Profile
.... 2.9 ECOG Performance Status Profile
.... 2.10 Genomic Variant Profile
.... 2.11 Homologous Recombination Deficiency Profile
.... 2.12 Imaging Disease Status Profile
.... 2.13 Karnofsky Performance Status Profile
.... 2.14 Lifestyle Profile
.... 2.15 Loss of Heterozygosity Profile
.... 2.16 Medication Administration Profile
.... 2.17 Microsatellite Instability Profile
.... 2.18 Molecular Tumor Board Review
.... 2.19 Primary Cancer Condition Profile
.... 2.20 Radiotherapy Summary Profile
.... 2.21 Secondary Cancer Condition Profile
.... 2.22 Serum Tumor Marker Level Category
.... 2.23 Surgical Procedure Profile
.... 2.24 Therapy Line Profile
.... 2.25 TNM Distant Metastases Category
.... 2.26 TNM Grade Category
.... 2.27 TNM Lymphatic Invasion Category
.... 2.28 TNM Perineural Invasion Category
.... 2.29 TNM Primary Tumor Category
.... 2.30 TNM Regional Nodes Category
.... 2.31 TNM Residual Tumor Category
.... 2.32 TNM Stage Group
.... 2.33 Tumor Board Review
.... 2.34 Tumor Marker Profile
.... 2.35 Tumor Mutational Burden Profile
.... 2.36 Tumor Neoantigen Burden Profile
.... 2.37 Venous Invasion Category
.... 2.38 Adjunctive Role
.... 2.39 Adverse Event Mitigation
.... 2.40 Age
.... 2.41 Age at Diagnosis
.... 2.42 Anonymized Entry
.... 2.43 Cancer Morphology
.... 2.44 Cancer Topography
.... 2.45 Cause of Death
.... 2.46 Combined With
.... 2.47 Contributors
.... 2.48 CTCAE Grade
.... 2.49 Cycles
.... 2.50 Data Completion Rate
.... 2.51 End of Records
.... 2.52 Gene Panel
.... 2.53 HGVS Version
.... 2.54 Is Primary Therapy
.... 2.55 Molecular Tumor Board CUP Characterization
.... 2.56 Molecular Tumor Board Molecular Comparison
.... 2.57 Molecular Tumor Board Therapeutic Recommendation
.... 2.58 Overall Survival
.... 2.59 Recist Is Interpreted
.... 2.60 Recurrence Of
.... 2.61 Recurrence Type
.... 2.62 Risk Assessment Score
.... 2.63 Therapy Line Intent
.... 2.64 Therapy Line Number
.... 2.65 Therapy Line Period
.... 2.66 Therapy Line Progression Date
.... 2.67 Therapy Line Progression-Free Survival
.... 2.68 Therapy Line Reference
.... 2.69 Tumor Board Specialization
.... 2.70 Tumor Marker Analyte
.... 2.71 Unknown Entry
.... 2.72 Adjunctive Therapy Roles
.... 2.73 Adverse Event Mitigation - Drugs
.... 2.74 Adverse Event Mitigation - Management
.... 2.75 Adverse Event Mitigation - Procedures
.... 2.76 Adverse Event Mitigation - Treatment Adjustment
.... 2.77 Adverse Event Mitigation Categories
.... 2.78 Antineoplastic Agents
.... 2.79 Cancer Imaging Methods
.... 2.80 Cancer Risk Assessment Methods
.... 2.81 Cause of Death Value Set
.... 2.82 Comorbidity Panels
.... 2.83 CTC Adverse Events
.... 2.84 Expected Drug Effects
.... 2.85 Exposure Agents
.... 2.86 ICD-10 Codes
.... 2.87 ICD-O-3 Morphology Behavior
.... 2.88 ICD-O-3 Topography
.... 2.89 Observation Body Sites Value Set
.... 2.90 Recreational Drugs
.... 2.91 Recurrence Type Value Set
.... 2.92 Risk Assessment Values
.... 2.93 Smoking status
.... 2.94 TNM Distant Metastasis Categories Value Set
.... 2.95 TNM Grade Categories Value Set
.... 2.96 TNM Grade Category Methods Value Set
.... 2.97 TNM Lymphatic Invasion Categories Value Set
.... 2.98 TNM Perineural Invasion Categories Value Set
.... 2.99 TNM Primary Tumor Categories
.... 2.100 TNM Regional Nodes Categories Value Set
.... 2.101 TNM Residual Tumor Categories Value Set
.... 2.102 TNM Serum Tumor Marker Level Categories Value Set
.... 2.103 TNM Venous Invasion Categories Value Set
.... 2.104 Treatment Termination Reasons
.... 2.105 Tumor Board Recommendations
.... 2.106 Tumor Marker Analytes
.... 2.107 Comorbidity Panels Code System
.... 2.108 To Be Determined Codes